Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment


Julio Rosenstock 1, Harpreet S Bajaj 1, Andrej Janež 1, Robert Silver 1, Kamilla Begtrup 1, Melissa V Hansen 1, Ting Jia 1, Ronald Goldenberg 1, NN1436-4383 Investigators

Main idea: Once-weekly treatment with insulin icodec had glucose-lowering efficacy and a safety profile similar to those of once-daily insulin glargine U100 in patients with type 2 diabetes.


It is thought that a reduction in the frequency of basal insulin injections might facilitate treatment acceptance and adherence among patients with type 2 diabetes. Insulin icodec is a basal insulin analogue designed for once-weekly administration that is in development for the treatment of diabetes. A 26-week, randomized, double-blind,double-dummy, phase 2 trial was conducted to investigate the efficacy and safety of once-weekly insulin icodec. The primary endpoint was the change in glycated hemoglobin level from baseline to week 26. A total of 247 participants were randomly assigned (1:1) to receive icodec or glargine. Baseline characteristics were similar in the two groups. There was no between-group difference in insulin-related key adverse events. Most adverse events were mild, and no serious events were deemed to be related to the trial medications.


Please enter your comment!
Please enter your name here